Abstract: This disclosure provides a configuration activation/deactivation method, a network device, and a terminal. The method includes: transmitting, to a terminal, activation/deactivation information for indicating activation/deactivation of multiple transmission configurations; wherein, the multiple transmission configurations are associated with configuration information of the activation/deactivation information, or a first field of the activation/deactivation information is used for indicating activation/deactivation of first configuration information that is same among the multiple transmission configurations.

Abstract: Compounds of general Formula S-1, S-2, S-3 and their pharmaceutically acceptable salts, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are synthesis, compositions, and uses of such compounds.

Abstract: The present disclosure discloses a gradient single-crystal positive electrode material, which has a chemical formula of LiNixCoyA1-x-yO2@mLiaZbOc, wherein 0<x<1, 0<y<1, 0<x+y<1, 0<m<0.05, 0.3<a?10, 1?b<4, and 1?c<15, A is at least one of Mn, Zr, Sr, Ba, W, Ti, Al, Mg, Y, and Nb, and Z is at least one of B, Al, Co, W, Ti, Zr, and Si. The atomic ratio of the content of Co on the surface of the single-crystal positive electrode material particle to the content of Ni+Co+A on the surface is greater than 0.4 and less than 0.8, and the atomic ratio of Co at a depth 10% of the radius from the surface of the single crystal positive electrode material particle is not less than 0.3; and the single-crystal positive electrode material particle has a roundness of greater than 0.4, and is free from sharp corners.

Abstract: Compounds of general Formula I, II, III, IV, V and their pharmaceutically acceptable salts, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are synthesis, compositions, and uses of such compounds.

Abstract: Tetrahydropyrido[3,4-d]pyrimidines compounds are provided that are potent HPK1 inhibitors. The compounds are useful to treat or prevent cancer and/or inflammatory and/or autoimmune diseases or symptoms thereof in mammals, particularly humans. The compounds have a chemical structure of the general Formula (I), (II), (III), (IV) or (V) or enantiomers or diastereomers or mixtures thereof or pharmaceutically acceptable salts thereof.

Abstract: An event processing method provided by an embodiment of the present disclosure determines M events, where each event is associated with a priority and a minimum working time, M is an integer greater than 1, and the minimum working time of each event is less than duration of a time slice; processes a first event within a first time slice, where the first event is an event having a highest priority among the M events; and in the case that processing duration of the first event reaches the minimum working time of the first event, determines to continue to process the first event within the first time slice, or determines to interrupt processing of the first event and processes a second event within the first time slice.

Abstract: The invention relates to novel glutamine analogs, a composition containing the glutamine analogs and the use thereof.

Abstract: The present invention provides recombinant bispecific antibodies designed to bind to a surface antigen on target cells and to an activating component on immune cells such as T cells. The bispecific antibodies comprise two polypeptide chains that contain Fv and Fab as antigen¬ binding fragments and a modified Fc region to facilitate heterodimer formation. In one embodiment, the bispecific antibodies further comprise protease cleavage sites and/or motifs that would cause steric occlusion of the antigen binding sites so that the antibodies would be activated only in a specific environment, e.g. in the vicinity of a tumor. In another embodiment, the bispecific antibodies comprise modified sequences that confer reduced binding affinity to CDS and/or cross-reactive binding to CDS on cells from different species.

Abstract: Proposed are a synchronous braking control method and system for carriages of a train, that are related to the field of electrical control. The synchronous braking control system includes a main controller, an electric energy conversion controller, and a shunt. During actual braking, the main controller obtains a real-time speed and real-time mass of the train, and determines whether the real-time speed is greater than a set speed. If not, the train is directly braked in a mechanical friction braking mode. If yes, an exciting current of a synchronous brake in each of the carriages of the train is adjusted by adjusting an input voltage of the synchronous brake, and unit braking forces of the carriages are controlled equal by using the adjusted exciting current, thereby realizing synchronous constant deceleration braking of the carriages.

Abstract: The application provides a method for improving nutrient supply of female floral branches of Populus deltoides artificial hybridization. According to the technical links of the hybridization operation, the method separately integrates and improves the cultivation of female floral branch nutrient-supply seedlings (i.e., grafting rootstocks of floral branches), the pre-management of female floral branch nutrient-supply seedlings, the hydroponic management of floral branches, the Marching between female floral branches and rootstocks, the management of female floral branch nutrient-supply seedlings and the hydroponic management of female floral branches, so the goal of improving the seed-setting rate and quality of poplar hybrid seeds which came from the floral branches cultured in water has been achieved.

Abstract: The invention relates to pyrimidinone derivatives of the general Formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.

Abstract: Provided are a liposome containing Eribulin or a pharmaceutically acceptable salt thereof and a preparation method therefor. An inner aqueous phase of the liposome contains Eribulin or a salt thereof, and one or more selected from ethylenediamine tetraacetic acid, phosphoric acid, pentetic acid, or salts thereof. Further provided are a pharmaceutical composition containing the aforementioned liposome and a preparation method therefor.

Abstract: Provided is a light-emitting diode and a method for preparing the same. The light-emitting diode includes an anode, a hole transport layer, a perovskite light-emitting layer, an electron transport layer and a cathode stacked in sequence, in which the perovskite light-emitting layer includes a first sublayer and a second sublayer stacked in sequence, with a material for forming the first sublayer including an inorganic perovskite material, and with a material for forming the second sublayer being an organic perovskite material.

Abstract: Disclosed are tricyclic compounds as bromodomain and extra-terminal (BET) inhibitors which are shown as formula I, their synthesis and their use for treating diseases. More particularly, disclosed are fused heterocyclic derivatives useful as inhibitors of BET, methods for producing such compounds and methods for treating diseases and conditions wherein inhibition of one or more BET bromodomains provides a benefit.

Abstract: The application provides a method for improving nutrient supply of female floral branches of Populus deltoides artificial hybridization. According to the technical links of the hybridization operation, the method separately integrates and improves the cultivation of female floral branch nutrient-supply seedlings (i.e., grafting rootstocks of floral branches), the pre-management of female floral branch nutrient-supply seedlings, the hydroponic management of floral branches, the Marching between female floral branches and rootstocks, the management of female floral branch nutrient-supply seedlings and the hydroponic management of female floral branches, so the goal of improving the seed-setting rate and quality of poplar hybrid seeds which came from the floral branches cultured in water has been achieved.

Abstract: The invention relates to compositions comprising a CD4 lymphocyte depleting agent; and methods of using the compositions to treat, prevent, reduce the severity of and/or slow the progression of a condition in a subject. The invention also relates to use of combinations of a CD4 lymphocyte depleting agent and at least one additional agent to treat, prevent, reduce the severity of and/or slow the progression of a condition in a subject. The additional agent may be an immune check point inhibitor, an adoptive immune therapeutic, an immune adjuvant, or an immune modulating agent, or their combinations.

Abstract: Disclosed are tricyclic compounds as bromodomain and extra-terminal (BET) inhibitors which are shown as formula I, their synthesis and their use for treating diseases. More particularly, disclosed are fused heterocyclic derivatives useful as inhibitors of BET, methods for producing such compounds and methods for treating diseases and conditions wherein inhibition of one or more BET bromodomains provides a benefit.

Abstract: The invention relates to compositions comprising a CD4 lymphocyte depleting agent; and methods of using the compositions to treat, prevent, reduce the severity of and/or slow the progression of a condition in a subject. The invention also relates to use of combinations of a CD4 lymphocyte depleting agent and at least one additional agent to treat, prevent, reduce the severity of and/or slow the progression of a condition in a subject. The additional agent may be an immune check point inhibitor, an adoptive immune therapeutic, an immune adjuvant, or an immune modulating agent, or their combinations.

Abstract: The present invention provides recombinant bispecific antibodies designed to bind to a surface antigen on target cells and to an activating component on immune cells such as T cells. The bispecific antibodies comprise two polypeptide chains that contain Fv and Fab as antigen-binding fragments and a modified Fc region to facilitate heterodimer formation In one embodiment, the bispecific antibodies further comprise protease cleavage sites and/or motifs that would cause steric occlusion of the antigen binding sites so that the antibodies would be activated only in a specific environment, e.g. in the vicinity of a tumor. In another embodiment, the bispecific antibodies comprise modified sequences that confer reduced binding affinity to CDS and/or cross-reactive binding to CDS on cells from different species.

Abstract: Compounds of Formula (I) and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.